Language selection

Search

Patent 3074538 Summary

Third-party information liability

Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.

Claims and Abstract availability

Any discrepancies in the text and image of the Claims and Abstract are due to differing posting times. Text of the Claims and Abstract are posted:

  • At the time the application is open to public inspection;
  • At the time of issue of the patent (grant).
(12) Patent Application: (11) CA 3074538
(54) English Title: METHOD FOR ADJUSTING LEVEL OF GALANIN IN BRAIN BY OPTIC NERVE LIGHT CONDUCTION
(54) French Title: METHODE POUR AJUSTER LE NIVEAU DE GALANINE DANS LE CERVEAU AU MOYEN DE LA CONDUCTION LUMINEUSE DES NERFS OPTIQUES
Status: Deemed Abandoned
Bibliographic Data
Abstracts

English Abstract


The present invention discloses a method for adjusting the level of galanin in
brain by
optic nerve light conduction, comprising the following step: controlling light
of different
wavelengths, different intensities and different frequencies to illuminate an
eye by a light
adjustrnent device, so that galanin receptors in the eye are activated to
produce signal
stimulation, and signals transmitted to the hypothalamic visual receiving area
via the optic
nerve can influence the level of galanin expression in the brain.


Claims

Note: Claims are shown in the official language in which they were submitted.


400-51 CA
We Claim:
1. A method for adjusting the level of galanin in brain by optic nerve light
conduction,
comprising the following step: controlling light of different wavelengths,
different
intensities and different frequencies to illuminate an eye by a light
adjustment device, so
that galanin receptors in the eye are activated to produce signal stimulation,
and signals
transmitted to the hypothalamic visual receiving area via the optic nerve can
influence the
level of galanin in the brain.
2. The method for adjusting the level of galanin in brain by optic nerve
conduction
according to Claim 1, wherein the light of different wavelengths, different
intensities and
different frequencies include visible light and invisible light.
3. The method for adjusting the level of galanin in brain by optic nerve light
conduction according to Claim 1, wherein the process of controlling the light
of different
wavelengths, different intensities and different frequencies to illuminate an
eye comprises:
gradually filtering natural light or simulated natural light according to
wavelengths in the
order from large to small and light intensities in the order from strong to
weak, until all
light are blocked or turned off.
4. The method for adjusting the level of galanin in brain by optic nerve light
conduction according to Claim 3, wherein the wavelengths are in the order from
large to
small as follows: red light: 605-720nm, orange light: 595-605nm, yellow light:
580-595nm,
yellow-green light: 560-580nm, green light: 500-560nm, blue-green light: 490-
500nm,
cyan light: 480-490nm, blue light: 450-480nm, and purple light: 400- 435nm.
5. The method for adjusting the level of galanin in brain by optic nerve light
conduction according to Claim 1, wherein the process of controlling the light
of different
wavelengths, different intensities and different frequencies to illuminate an
eye comprises:
gradually recovering the light source according to wavelengths in the order
from small to
large and light intensities in the order from weak to strong in the absence of
light source,
until the natural light or the simulated natural light gradually illuminates
the human eye.
6. The method for adjusting the level of galanin in brain by optic nerve light
conduction according to claim 1, wherein =the light adjustment device
comprises a light
source, light filters and a light filter adjustment assembly, wherein the
light source is natural
light or simulated natural light simulated using light-emitting elements; the
light filters are
CA 3074538 2020-03-04

400-51 CA
multiple in number, which are used for filtering light of different
wavelengths respectively;
and the light filter adjustment assembly is used for adjusting the position of
the multiple
light filters, to enable the light filters to be located between the light
source and the eye or
be removed between the light source and the eye.
7. The method for adjusting the level of galanin in brain by optic nerve light
conduction according to Claim 1, wherein the light adjustment device comprises
a light
source, a light wavelength control unit and a light frequency control unit,
wherein the light
source is an array of light-emitting elements of different wavelengths; the
light wavelength
control unit controls the light-emitting elements of different wavelengths to
emit light
respectively through current connection; and the light frequency control unit
controls the
light-emitting intensities of the light-emitting elements of different
wavelengths
respectively through current pulse width control elements.
CA 3074538 2020-03-04

Description

Note: Descriptions are shown in the official language in which they were submitted.


400-51 CA
Method for Adjusting Level of Galanin in Brain by Optic Nerve Light Conduction
Technical Field
The present invention relates to a method for adjusting the level of galanin
in brain by
optic nerve light conduction.
Background
Galanin (GAL) is a regulatory peptide consisting of 30/29 (human/rodent) amino
acids. GAL is broadly distributed in the central and peripheral nervous
systems as well as
in non-neuronal tissues. Galanin peptide has a wide range of nonneuronal
functions as well
as classic neuro-modulatory roles. Galanin is important for a variety of
biological functions
such as feeding, pain processing, endocrine functions, neuroprotection, sleep,
mood change,
and sexual reproduction. It is believed that galanin expression level might be
especially
closely related to the pathogenesis of Alzheimer's disease (AD), anxiety and
depression,
insomnia, and sensitivity of pain caused by nerve injury.
Galanin has been shown to exerts its effects on numerous biological and
pathophysiological processes through three G-protein coupled receptors GLAR 1-
3. In the
cornea, GALR1-3 are detected in the stratum basal of epithelial cells, stromal
cells and
endothelial cells, and adjacent conjunctiva (Distribution of galanin receptors
in the human
eye, (Falk Schrodl, et al, Experimental Eye Research 138 (2015) 42-51). In the
iris,
GALR1-3 are found in the sphincter and dilator, and also in iris vessels. In
the ciliary body,
GALR1 are found only in non-pigmented epithelial cells, while GALR3 are found
in the
ciliary muscles and vessels. In the retina, GALR1's are present in a large
number of cells
and GLAR 2's in a small number of cells of GALR2; GALR3 's are also present in
a small
number of neurons and GALR2's are also found around the retinal vessels and
retinal
pigment epithelial cells together with GALR3. In the choroid, the presence of
GALR1-3
are detected in both endogenous choroidal neurons and nerve fibers of the
choroidal stroma,
and these three receptors may also be detected around the choroidal vessels,
while the
choroidal vascular layer seems to be only containing GALR3. Also GALR 1-3
present in
the eye might be related to the wound healing or inflammation process,
vascular dynamics
CA 3074538 2020-03-04

400-51 CA
and signal transduction.
Since the human eyes convert visual input into electrical information and
route this
information to the brain, research has shown that light of different
wavelengths and
frequencies (including visible light and invisible light) could generate
different signal
stimulation for GALR.
Further, research shows that light of different wavelengths and frequencies
(including
visible light and invisible light) may generate different signal stimulations
for GALR. A
marked alternation in galanin expression in the brain is observed under a
number of
conditions. This suggests a role for the neuropeptide and tis receptors for a
novel
therapeutic method. To be more specific, adjusting GAL in the brain by using
GALR in the
eye could influence the galanin expression in the brain. Due to the critical
role of galanin
in many biological processes, this method could have a wide range of
applications.
Summary
In view of this, the present invention provides a method for adjusting the
level of
galanin in the brain by optic nerve light conduction. The key idea or
procedure is to use
light of different wavelengths, different intensities and different
frequencies to illuminate
an eye by a light adjustment device in order to activate the galanin receptors
in the eye to
generate signals transmitted to the hypothalamic via the optic nerve. The
light of different
wavelengths, different intensities and different frequencies include visible
light and
invisible light.
The process of controlling the light of different wavelengths, different
intensities and
different frequencies to illuminate an eye will be done through filtering
natural light or
simulated natural light according to wavelengths in the order form large to
small and light
intensities and from strong to weak, until all light is blocked or turned off.
The process of controlling the light of different wavelengths, different
intensities and
different frequencies to illuminate an eye also comprises gradually recovering
the light
source according to wavelengths in the order from small to large and light
intensities from
weak to strong in the absence of other light source, until the natural light
or the simulated
natural light gradually illuminates the human eye.
CA 3074538 2020-03-04

400-51 CA
The wavelengths are in the order from large to small as follows: red light:
605-720nm,
orange light: 595-605nm, yellow light: 580-595nm, yellow-green light: 560-
580nm, green
light: 500-560nm, blue-green light: 490-500nm, cyan light: 480-490nm, blue
light: 450-
480nm, and purple light: 400- 435nm.
The light adjustment device comprises a light source, light filters and a
light filter
adjustment assembly; wherein the light source is natural light or simulated
natural light
using light-emitting devices; light filters which are used to filter light of
different
wavelengths respectively; and the light filter adjustment assembly is used for
adjusting the
position of the multiple light filters in order for the light filters to be
located either between
the light source and the eye or be removed completely.
The light adjustment device can be configured into an eyeshade-type product,
and a
conventional mobile or wearable component may be also selected as the light
filter
adjustment device.
In summary, the light adjustment apparatus comprises a light source, a light
wavelength control unit and a light frequency control unit, wherein the light
source of the
device is an array of light-emitting elements of different wavelengths; the
light wavelength
control unit controls the light-emitting elements of different wavelengths to
emit light
respectively through current connection; and the light frequency control unit
controls the
light-emitting intensities of the light-emitting elements of different
wavelengths
respectively through current pulse width. In the present invention, by
applying repeated
and well controlled light stimulation on the eye through light source signals
of different
wavelengths and frequencies, GALR in the eye may be activated, thus achieving
the
purpose of adjusting the level of the GAL in brain through optic nerve
conduction.
Detailed Description
Embodiment 1
A method for adjusting the level of galanin in brain by optic nerve light
conduction,
comprising the following step: controlling light of different wavelengths and
different
frequencies to illuminate an eye by a light adjustment device, so that galanin
receptors in
the eye are activated to produce signal stimulation, and signals transmitted
to the
CA 3074538 2020-03-04

400-51 CA
hypothalamic visual receiving area via the optic nerve can then influence the
level of
galanin expression in the brain.
The light adjustment device comprises a light source, multiple light filters
and a light
filter adjustment assembly, wherein the light source is simulated natural
light using light-
emitting elements; the light filters are multiple in number, which are used
for filtering light
of different wavelengths respectively; and the light filters are mounted on
the light filter
adjustment assembly; and the light filter adjustment assembly is used for
adjusting the
position of the multiple light filters to enable the light filters to be
located between the light
source and the eye or to be removed when necessary.
The light adjustment device is configured into an eyeshade-type product and is
worn
on the head while in use. The simulated natural light emitted by the light-
emitting elements
is made to illuminate the eye; then the light filter adjustment assembly is
controlled to
gradually superimpose the light filters between the light source and the eye
according to
wavelengths in the order from large to small to filter light, until all light
are blocked or
turned off.
The wavelengths are in the order from large to small as follows: red light:
605-720nm,
orange light: 595-605nm, yellow light: 580-595nm, yellow-green light: 560-
580nm, green
light: 500-560nm, blue-green light: 490-500nm, cyan light: 480-490nm, blue
light: 450-
480nm, and purple light: 400- 435nm.
Further, the light filters may be gradually removed according to wavelengths
in the
order from small to large, until the simulated natural light gradually
illuminates the human
eye.
Embodiment 2
A method for adjusting the level of galanin in brain by optic nerve light
conduction,
comprising the following step: controlling light of different wavelengths and
different
frequencies to illuminate an eye by a light adjustment device, so that galanin
receptors in
the eye are made to produce signal stimulation, and signals transmitted to the
hypothalamic
visual receiving area via the optic nerve to influence the level of galanin in
the brain.
The light adjustment device comprises a light source, a light wavelength
control unit
and a light frequency control unit, wherein the light source is an array of
light-emitting
elements of different wavelengths; LED lamps of different light wavelengths
may be
CA 3074538 2020-03-04

400-51 CA
arranged to form the array; the light wavelength control unit may select any
form of current
control elements to control currents of light-emitting elements of different
wavelengths
respectively, so that light-emitting elements of different wavelengths are
turned on or
turned off, and then illumination of light of different wavelengths is
achieved; and the light
frequency control unit may be set to control and adjust the light-emitting
intensities of the
light-emitting elements of different wavelengths respectively.
The light adjustment device is configured into an eyeshade-type product
(encapsulated in the eyeshade shell) and is worn on the outside of the eye
while in use; all
light-emitting elements in the array are controlled to emit light through
current, the
simulated natural light is made to illuminate the eye, then the light
frequency control unit
is controlled to reduce the light-emitting intensity of the light-emitting
element of the
maximum wavelength, the light-emitting element is controlled to be turned off
by the light
wavelength control unit, and the above-mentioned operation is repeatedly
performed on
the light-emitting elements of different wavelengths according to wavelengths
in the order
from large to small, until all light are turned off.
The wavelengths are in the order from large to small as follows: red light:
605-720nm,
orange light: 595-605nm, yellow light: 580-595nm, yellow-green light: 560-
580nm, green
light: 500-560nm, blue-green light: 490-500nm, cyan light: 480-490nm, blue
light: 450-
480nm, and purple light: 400- 435nm.
Further, the light-emitting elements may be gradually turned on according to
wavelengths in the order from small to large and light intensities in the
order from weak to
strong, until the simulated natural light gradually illuminates the human eye.
By adjustment of light of different wavelengths and different frequencies,
GALR 1-
3 in the eye may be activated to achieve the purpose of adjusting the level of
the GAL in
brain through optic nerve conduction. Since GAL is involved in mediating a
variety of
biological functions such as feeding, sense of pain, endocrine,
neuroprotection, learning
and memory, sleep, mood, sexuality and reproduction, it is expected to realize
the
intervention of biological response in vivo by adjustment of light of
different wavelengths
and different frequencies as a novel therapeutic measure.
Embodiment 3
A method for adjusting the level of galanin in brain by optic nerve light
conduction,
CA 3074538 2020-03-04

400-51 CA
comprising the following step: making blue light of 8-10Hz and red light of
0.5-411z
illuminate an eye by a light adjustment device in order to activate the GLAR 1-
3 in the eye
to achieve signal stimulation; and signals transmitted to the hypothalamic
visual receiving
area via the optic nerve can influence the level of galanin in the brain.
The light adjustment device comprises a light source, a light wavelength
control unit
and a light frequency control unit, wherein the light source is an array
formed by arranging
red light LED lamps and blue light LED lamps; the light wavelength control
unit may select
any form of current control elements to control currents of the red light LED
lamps and the
blue light LED lamps respectively, so that the red light LED lamps or the blue
light LED
lamps are turned on or turned off; and the light frequency control unit may
select any form
of current pulse width control elements to control the light-emitting
intensities of the red
light LED lamps and the blue light LED lamps respectively, thus adjusting the
intensities
of light.
The light adjustment device is configured into an eyeshade-type product and is
worn
on the eye while in use, the red light LED lamps in the array are controlled
to emit light
through the current, and then the light frequency control unit is controlled
to adjust the
frequency to 0.5-4Hz, thus reducing the level of galanin in the brain and
promoting sleep.
The blue light LED lamps in the array are controlled to emit light through the
current, and
then the light frequency control unit is controlled to adjust the frequency to
8-10Hz, thus
increasing the level of galanin in the brain and promoting wakeup.
The above description of the disclosed embodiments enables those skilled to
realize
or use the present invention. The general principle defined herein can be
realized in other
embodiments without departing from the spirit or scope of the present
invention. Therefore,
the present invention will not be limited to these embodiments shown herein,
but will
conform to the widest scope consistent with the principle and novel features
disclosed
herein.
CA 3074538 2020-03-04

Representative Drawing

Sorry, the representative drawing for patent document number 3074538 was not found.

Administrative Status

2024-08-01:As part of the Next Generation Patents (NGP) transition, the Canadian Patents Database (CPD) now contains a more detailed Event History, which replicates the Event Log of our new back-office solution.

Please note that "Inactive:" events refers to events no longer in use in our new back-office solution.

For a clearer understanding of the status of the application/patent presented on this page, the site Disclaimer , as well as the definitions for Patent , Event History , Maintenance Fee  and Payment History  should be consulted.

Event History

Description Date
Inactive: Office letter 2024-03-28
Inactive: Office letter 2024-03-28
Letter Sent 2024-03-04
Deemed Abandoned - Failure to Respond to Maintenance Fee Notice 2023-09-06
Deemed Abandoned - Failure to Respond to an Examiner's Requisition 2023-05-29
Letter Sent 2023-03-06
Examiner's Report 2023-01-27
Inactive: Report - No QC 2023-01-24
Letter Sent 2022-01-27
All Requirements for Examination Determined Compliant 2022-01-05
Request for Examination Requirements Determined Compliant 2022-01-05
Request for Examination Received 2022-01-05
Inactive: Cover page published 2021-09-08
Application Published (Open to Public Inspection) 2021-09-04
Letter sent 2021-08-24
Filing Requirements Determined Compliant 2021-08-24
Inactive: Filing certificate correction 2021-06-29
Inactive: COVID 19 - Deadline extended 2020-08-19
Inactive: COVID 19 - Deadline extended 2020-08-06
Inactive: COVID 19 - Deadline extended 2020-07-16
Inactive: COVID 19 - Deadline extended 2020-07-02
Inactive: IPC assigned 2020-06-25
Inactive: First IPC assigned 2020-06-25
Inactive: COVID 19 - Deadline extended 2020-06-10
Inactive: COVID 19 - Deadline extended 2020-05-28
Inactive: COVID 19 - Deadline extended 2020-05-14
Inactive: COVID 19 - Deadline extended 2020-04-28
Letter sent 2020-04-01
Filing Requirements Determined Compliant 2020-04-01
Common Representative Appointed 2020-03-04
Inactive: Pre-classification 2020-03-04
Small Entity Declaration Determined Compliant 2020-03-04
Application Received - Regular National 2020-03-04
Inactive: QC images - Scanning 2020-03-04

Abandonment History

Abandonment Date Reason Reinstatement Date
2023-09-06
2023-05-29

Maintenance Fee

The last payment was received on 2022-02-22

Note : If the full payment has not been received on or before the date indicated, a further fee may be required which may be one of the following

  • the reinstatement fee;
  • the late payment fee; or
  • additional fee to reverse deemed expiry.

Please refer to the CIPO Patent Fees web page to see all current fee amounts.

Fee History

Fee Type Anniversary Year Due Date Paid Date
Application fee - small 2020-03-04 2020-03-04
Request for examination - small 2024-03-04 2022-01-05
MF (application, 2nd anniv.) - small 02 2022-03-04 2022-02-22
Owners on Record

Note: Records showing the ownership history in alphabetical order.

Current Owners on Record
TONG LI
Past Owners on Record
XIAOGANG WANG
Past Owners that do not appear in the "Owners on Record" listing will appear in other documentation within the application.
Documents

To view selected files, please enter reCAPTCHA code :



To view images, click a link in the Document Description column. To download the documents, select one or more checkboxes in the first column and then click the "Download Selected in PDF format (Zip Archive)" or the "Download Selected as Single PDF" button.

List of published and non-published patent-specific documents on the CPD .

If you have any difficulty accessing content, you can call the Client Service Centre at 1-866-997-1936 or send them an e-mail at CIPO Client Service Centre.


Document
Description 
Date
(yyyy-mm-dd) 
Number of pages   Size of Image (KB) 
Abstract 2020-03-04 1 16
Description 2020-03-04 6 397
Claims 2020-03-04 2 105
Cover Page 2021-09-08 1 28
Courtesy - Office Letter 2024-03-28 2 189
Commissioner's Notice - Maintenance Fee for a Patent Application Not Paid 2024-04-15 1 563
Courtesy - Filing certificate 2020-04-01 1 579
Courtesy - Filing certificate 2021-08-24 1 578
Courtesy - Acknowledgement of Request for Examination 2022-01-27 1 424
Commissioner's Notice - Maintenance Fee for a Patent Application Not Paid 2023-04-17 1 560
Courtesy - Abandonment Letter (R86(2)) 2023-08-07 1 560
Courtesy - Abandonment Letter (Maintenance Fee) 2023-10-18 1 550
New application 2020-03-04 10 247
Filing certificate correction 2021-06-29 3 68
Request for examination 2022-01-05 4 76
Examiner requisition 2023-01-27 3 138